Polomar Health Services Inc. reported its actual financial results for the fiscal year ending December 31, 2024, showcasing a significant increase in revenue, which rose to $1.5 million from $41,844 in the previous year. The revenue in 2023 was generated from pharmacy operations. The company has indicated that it does not expect significant revenues until it can raise capital to enhance the distribution and demand for its database and services. If funding is secured, Polomar plans to engage in partnerships with larger marketing agencies and influencers to boost its platform's visibility. Operating expenses experienced a substantial increase, reaching $1.3 million in 2024, compared to $478,382 in 2023. This rise was primarily attributed to payroll expenses amounting to $380,476, legal and accounting fees of $198,878 related to a merger and associated filings, and consulting fees of $130,399. These results reflect the company's strategic movements and financial adjustments as it navigates its business operations and future growth plans.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.